WebMar 28, 2024 · In a recent clinical trial, CyPath ® Lung showed 92% sensitivity and 87% specificity in high-risk patients who had nodules smaller than 20 millimeters or no … WebJan 24, 2024 · BioAffinity Technologies Inc. shares were up 44% to $2.29 on Tuesday after the company said it saw positive results in a clinical trial studying CyPath Lung, its non-invasive early-stage lung ...
bioAffinity Technologies Executes Agreement with Fosun Long …
WebMar 28, 2024 · In a recent clinical trial, CyPath ® Lung showed 92% sensitivity and 87% specificity in high-risk patients who had nodules smaller than 20 millimeters or no nodules in the lung, with an area ... WebMar 14, 2024 · CyPath Lung is currently licensed to CAP/CLIA-certified Precision Pathology Services of San Antonio for sale as a laboratory developed test. In a multi-site, 150-patient validation study with Stages 1-4 cancer patients, CyPath Lung demonstrated 82% sensitivity and 88% specificity overall. Sensitivity is the ability to correctly identify cancer ... bupivacaine dosage
CyPath Patient CyPath™ Lung - Precision Pathology
WebMar 31, 2024 · Revenue for the fourth quarter of 2024 was approximately $2,500, compared with no revenue for the prior-year period. Revenue was derived from the sale of CyPath® Lung as a Laboratory Developed ... WebOct 16, 2024 · Biotech company bioAffinity Technologies and medical device maker Smiths Medical have partnered to boost patient care with at-home collection of sputum, which can be analysed by a non-invasive flow cytometry diagnostic test for lung cancer, CyPath Lung. The diagnostic test is being developed as a Laboratory Developed Test (LDT) by Texas … WebJun 10, 2024 · CyPath® Lung is a flow cytometric test to aid in the diagnosis of lung cancer. Patients collect sputum samples non-invasively at home, a particular benefit during the … bupivacaine brand name